LSK Global PS joint clinical development agreement
All clinical practice from prevention to treatment… Establishment of clinical development system
Daewoong Pharmaceutical and LSK Global Pharma Services, a clinical trial consignment organization, passed a memorandum of understanding (MOU) for joint clinical development cooperation for the clinical trial of’Hoy Star Tablet (ingredient name: Camostat mesylate)’ for COVID-19 treatment. Signed the day.
This MOU aims to establish a joint clinical development system through cooperation in Hoystar’s participation in the clinical development of COVID-19 treatment, sharing human resources and infrastructure for clinical trials, and establishing clinical strategies.
LSK Global PS performs tasks throughout clinical trials such as monitoring, operation of clinical trials, data management, statistics, etc., and is in charge of some or the entire process in several clinical trials of Hoystar on the prevention and treatment of COVID-19. It is planning to cooperate on strategies and development directions for expanding global clinical trials not only in Korea but also overseas.
Hoy Star Tablet is a drug that Daewoong Pharmaceutical is developing as the first oral COVID-19 treatment, and has confirmed the improvement of clinical symptoms and rapid virus removal speed in patients with mild Corona 19 in Korea. Currently, phase 2/3 clinical trials have been initiated for large-scale patients, and a preventive clinical trial will be conducted so that not only patients, but also close contacts, suspected symptoms, and self-isolators can develop a drug that should be taken the fastest. In addition, a large-scale national study (Korean Covid-19 Trial 1) clinical trial on severe corona19 patients that has not been conducted in Korea is also being conducted.
Seung-ho Jeon, president of Daewoong Pharmaceutical, said, “Hoi Star Tablet is a drug that can be used in a wide range of patients, and we expect that it will greatly contribute to overcoming the global COVID-19 pandemic. Through this collaboration, we will complete clinical trials quickly and accurately. I will try to provide a cure for Corona 19 to my patients.”
Lee Young-jak, representative of LSK Global PS, said, “We will contribute to the end of Corona 19 by in charge of clinical trials related to Corona 19 of Daewoong Pharmaceutical including Hoy Star. With a sense of mission to overcome Corona 19 as soon as possible, And I will do my best to achieve it successfully.”
Copyright holder © Uihyeop Shinmun Unauthorized reproduction and redistribution prohibited